List of Excipients in Branded Drug GEMCITABINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Hospira Inc	GEMCITABINE	gemcitabine	0409-0181	HYDROCHLORIC ACID
Hospira Inc	GEMCITABINE	gemcitabine	0409-0181	SODIUM HYDROXIDE
Hospira Inc	GEMCITABINE	gemcitabine	0409-0181	WATER
Accord Healthcare Inc	GEMCITABINE	gemcitabine	16729-391	ALCOHOL
Accord Healthcare Inc	GEMCITABINE	gemcitabine	16729-391	HYDROCHLORIC ACID

Generic Drugs Containing GEMCITABINE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	gemcitabine	0143-9340	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	gemcitabine	0143-9340	SODIUM HYDROXIDE
Hikma Pharmaceuticals USA Inc	gemcitabine	0143-9340	WATER
Hikma Pharmaceuticals USA Inc	gemcitabine	0143-9394	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	gemcitabine	0143-9394	MANNITOL

What are the Most Frequently-Used Excipients in GEMCITABINE?

# Of NDCs	Excipient
17	HYDROCHLORIC ACID
11	MANNITOL
11	SODIUM ACETATE
17	SODIUM HYDROXIDE
8	WATER

Excipient Strategy and Commercial Opportunities for Gemcitabine

Last updated: February 28, 2026

What constitutes the excipient strategy for gemcitabine?

Gemcitabine is a nucleoside analog used as a chemotherapeutic agent. Its formulation involves specific excipients designed to stabilize the active pharmaceutical ingredient (API), optimize delivery, and ensure patient safety. Common excipients in gemcitabine formulations include sodium chloride and sodium phosphate buffers to maintain pH, stabilizers such as polysorbates, and preservatives if necessary.

Standard formulations are typically aqueous solutions with an isotonic sodium chloride solution to match physiological osmolarity. In some cases, buffers like sodium phosphate are used to maintain pH within a narrow range (approximately pH 4.0 to 4.5). Excipients such as mannitol help stabilize the formulation and prevent API degradation.

How are excipient choices evolving for gemcitabine?

Recent trends aim to reduce excipient-related toxicity, improve stability, and expand administration routes. Liposomal formulations and nanoparticle carriers substitute traditional excipients with lipid-based components or polymers to enhance pharmacokinetics. These carriers use phospholipids, PEGylated lipids, or biodegradable polymers as excipients.

In phase development pipelines, excipients focusing on reducing hypersensitivity or infusion-related reactions include substituting polysorbates for alternatives like poloxamers. Efforts also target reducing immunogenicity and simplifying excipient profiles for better stability and shelf life.

What are the commercial opportunities related to excipient development?

1. Liposomal and Nanoparticle Formulations: The market for liposomal gemcitabine formulations is growing. These formulations often involve specialized excipients like phospholipids and PEGs, which can extend patent protection and command premium pricing.

2. Excipients for Stability: Developing novel stabilizers that prolong shelf life or enable storage at room temperature creates opportunities. This is especially pertinent in emerging markets with limited cold chain infrastructure.

3. Reduced Toxicity Excipient Systems: Innovating non-immunogenic excipients reduces adverse reactions, expanding patient eligibility and improving safety profiles—valuable in combination therapies where cumulative toxicity matters.

4. Depot and Sustained-Release Formulations: Excipients that enable slow or targeted release of gemcitabine, such as biodegradable polymers, can open markets in outpatient treatments, reducing hospital visits and delivery costs.

5. Regulatory Incentives: Excipients compliant with latest safety standards and with established safety profiles facilitate faster regulatory approval, providing competitive advantage.

How does the choice of excipients impact patentability and market exclusivity?

Patents can cover unique excipient combinations, novel stabilizers, or delivery mechanisms incorporating specific excipients. For example, a liposomal formulation with proprietary lipid composition can extend patent life beyond the original API patent expiration. Regulatory exclusivity may also be secured through formulations with innovative excipient profiles that demonstrate improved safety or efficacy.

What are the main challenges in excipient development for gemcitabine?

• Ensuring excipients do not interact adversely with gemcitabine, leading to instability or reduced efficacy.
• Meeting strict regulatory standards for excipient safety, especially in parenteral formulations.
• Developing scalable manufacturing processes for complex excipient systems.
• Navigating patent landscapes to avoid infringement while securing own patents.

Summary of key data points

Aspect	Details
Typical excipients in gemcitabine	Sodium chloride, sodium phosphate, polysorbates, mannitol
Formulation types	Injection solutions, liposomal, nanoparticle carriers
Trends	Liposomal forms, reduced immunogenic excipients, sustained-release systems
Regulatory considerations	Safety profiles, stability, compatibility with API
Market potential	$2.5 billion (2019 global gemcitabine market estimate)

Key Takeaways

• Excipients in gemcitabine formulations focus on stability, safety, and delivery optimization.
• Liposomal and nanoparticle carriers are primary avenues for excipient innovation.
• Opportunities exist in developing safer excipients, extended-release systems, and formulations suited for emerging markets.
• Patent strategies leverage unique excipient combinations and delivery systems.
• Regulatory hurdles emphasize safety and compatibility; innovations in these areas can unlock new markets.

FAQs

Q1: What are the primary excipients used in gemcitabine injections?
A: Sodium chloride, sodium phosphate buffers, polysorbates, and stabilizers like mannitol are common.

Q2: How can excipient choices enable new gemcitabine formulations?
A: They allow for liposomal or nanoparticle delivery, improve stability, reduce toxicity, and enable sustained release.

Q3: What opportunities exist for excipient innovation in gemcitabine?
A: Developing non-immunogenic stabilizers, room-temperature stable formulations, and biodegradable polymers for depot systems.

Q4: How do excipients influence patent protection?
A: Unique excipient combinations or delivery mechanisms can be patented, extending market exclusivity.

Q5: What regulatory concerns are associated with excipients in gemcitabine?
A: Ensuring excipients are safe, compatible with API, and compliant with guidelines for parenteral formulations.

---

References

[1] World Health Organization. (2019). Guidelines on the quality, safety, and efficacy of pharmaceutical excipients. WHO Press.